Companies ANI Pharmaceuticals Inc
ANI Pharmaceuticals (ANIP): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me ANI Pharmaceuticals Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers83rd pct.Of 6 peer CEOs
CEO pay, last three years
- $8,078,353FY2023
- $8,859,402FY2024
- $10,278,620FY2025
CEO total pay was $10,278,620 in fiscal 2025, up from $8,859,402 in fiscal 2024.
FY2025: salary $837,409 · bonus $0 · stock awards $7,848,711 · option awards $0
Executives and directors
Christopher Mutz · SVPMeredith Cook · General CounselNikhil Lalwani · CEOOri Gutwerg · SVPStephen Carey · CFOAntonio R. Pera · Independent DirectorJeanne A. Thoma · Independent DirectorMatthew J. Leonard · Independent DirectorMuthusamy Shanmugam · DirectorPatrick Walsh · Independent DirectorRenee P. Tannenbaum · Independent DirectorThomas J. Haughey · Independent Director
Frequently asked questions
Who was the highest-paid executive at ANI Pharmaceuticals Inc in fiscal 2025?
As disclosed, Nikhil Lalwani (President and Chief Executive Officer) was the highest-paid executive at ANI Pharmaceuticals Inc in fiscal 2025, with total compensation of $10,278,620.
How does ANI Pharmaceuticals Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Nikhil Lalwani's total compensation ranked at the 83rd percentile of ANI Pharmaceuticals Inc's disclosed peer group.
What is ANI Pharmaceuticals Inc's CEO-to-median employee pay ratio?
As disclosed, ANI Pharmaceuticals Inc's CEO-to-median employee pay ratio was 114:1.
How did shareholders vote on ANI Pharmaceuticals Inc's executive compensation?
As disclosed, 92.78% of shareholders supported ANI Pharmaceuticals Inc's executive compensation in the latest say-on-pay vote.
How much does ANI Pharmaceuticals Inc spend in total on board compensation for fiscal 2025?
As disclosed, ANI Pharmaceuticals Inc reported total board compensation of $2,007,938 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nikhil Lalwani | $837,409 | $0 | $7,848,711 | $0 | $1,572,500 | $0 | $20,000 | $10,278,620 |
| President and Chief Executive Officer | ||||||||
| Christopher Mutz | 471,625 | 0 | 2,130,319 | 0 | 477,750 | 0 | 317,000 | 3,396,694 |
| Senior Vice President, Head of Rare Disease | ||||||||
| Stephen Carey | 521,031 | 0 | 2,130,319 | 0 | 582,912 | 0 | 17,600 | 3,251,862 |
| Senior Vice President, Finance and Chief Financial Officer | ||||||||
| Meredith Cook | 462,052 | 0 | 1,457,614 | 0 | 382,032 | 0 | 16,724 | 2,318,421 |
| Senior Vice President, General Counsel and Corporate Secretary | ||||||||
| Ori Gutwerg | 479,870 | 0 | 1,345,411 | 0 | 484,278 | 0 | 0 | 2,309,559 |
| Senior Vice President, Generics | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Nikhil Lalwani | $10,278,620 | $8,859,402 | $8,078,353 | ↑ +1,419,218 |
| Christopher Mutz | 3,396,694 | 2,417,672 | 1,914,451 | ↑ +979,022 |
| Stephen Carey | 3,251,862 | 2,850,468 | 2,576,088 | ↑ +401,394 |
| Meredith Cook | 2,318,421 | 2,022,480 | — | ↑ +295,941 |
| Ori Gutwerg | 2,309,559 | 2,107,942 | 1,941,690 | ↑ +201,617 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Attract and retain: Offer a total compensation program that flexibly adapts to changing economic, regulatory and organizational conditions, and takes into consideration the compensation practices of peer companies. Pay for performance: Provide a significant portion of compensation through variable compensation that is at-risk and tied to our financial performance, strategic objectives or stock price. Align executive interests with those of our Stockholders: A significant portion of total compensation is either earned based on our overall financial and operating performance or varies based on our stock price, which contributes to value creation for our Stockholders.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | True |
| Anti-hedging | False |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Christopher Mutz | RSU | 2025-02-12 | — | — | 24,808 | — | $1,480,541 |
| Ori Gutwerg | RSU | 2025-02-12 | — | — | 15,668 | — | 935,066 |
| Nikhil Lalwani | RSU | 2025-02-12 | — | — | 91,399 | — | 5,454,692 |
| Ori Gutwerg | PSU | 2025-02-12 | 2,611 | 5,222 | — | 10,444 | 410,345 |
| Meredith Cook | RSU | 2025-02-12 | — | — | 16,974 | — | 1,013,008 |
| Stephen Carey | RSU | 2025-02-12 | — | — | 24,808 | — | 1,480,541 |
| Meredith Cook | PSU | 2025-02-12 | 2,829 | 5,658 | — | 11,316 | 444,606 |
| Stephen Carey | PSU | 2025-02-12 | 4,134 | 8,269 | — | 16,538 | 649,778 |
| Christopher Mutz | PSU | 2025-02-12 | 4,134 | 8,269 | — | 16,538 | 649,778 |
| Nikhil Lalwani | PSU | 2025-02-12 | 15,233 | 30,466 | — | 60,932 | 2,394,018 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Christopher Mutz | $1,480,541 | $649,778 | $0 | 30.5% |
| Ori Gutwerg | 935,066 | 410,345 | 0 | 30.5% |
| Nikhil Lalwani | 5,454,692 | 2,394,018 | 0 | 30.5% |
| Meredith Cook | 1,013,008 | 444,606 | 0 | 30.5% |
| Stephen Carey | 1,480,541 | 649,778 | 0 | 30.5% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christopher Mutz | RSU | 1,619 | — | $127,804 |
| Ori Gutwerg | RSU | 1,619 | — | 127,804 |
| Stephen Carey | RSU | 2,823 | — | 222,848 |
| Meredith Cook | RSU | 4,820 | — | 380,491 |
| Christopher Mutz | RSU | 4,857 | — | 383,412 |
| Ori Gutwerg | RSU | 4,857 | — | 383,412 |
| Meredith Cook | RSU | 6,080 | — | 479,955 |
| Nikhil Lalwani | RSU | 8,338 | — | 658,202 |
| Stephen Carey | RSU | 8,469 | — | 668,543 |
| Christopher Mutz | RSU | 8,685 | — | 685,594 |
| Ori Gutwerg | RSU | 8,685 | — | 685,594 |
| Ori Gutwerg | RSU | 9,842 | — | 776,927 |
| Meredith Cook | RSU | 9,842 | — | 776,927 |
| Ori Gutwerg | RSU | 10,444 | — | 824,449 |
| Ori Gutwerg | RSU | 11,073 | — | 874,103 |
| Meredith Cook | RSU | 11,073 | — | 874,103 |
| Meredith Cook | RSU | 11,316 | — | 893,285 |
| Stephen Carey | RSU | 12,158 | — | 959,753 |
| Christopher Mutz | RSU | 12,526 | — | 988,802 |
| Ori Gutwerg | Option | 13,204 | 31.49 | — |
| Christopher Mutz | RSU | 14,093 | — | 1,112,501 |
| Stephen Carey | RSU | 14,316 | — | 1,130,105 |
| Ori Gutwerg | RSU | 15,668 | — | 1,236,832 |
| Stephen Carey | RSU | 16,106 | — | 1,271,408 |
| Stephen Carey | RSU | 16,538 | — | 1,305,510 |
| Christopher Mutz | RSU | 16,538 | — | 1,305,510 |
| Meredith Cook | RSU | 16,974 | — | 1,339,928 |
| Stephen Carey | RSU | 24,808 | — | 1,958,344 |
| Christopher Mutz | RSU | 24,808 | — | 1,958,344 |
| Nikhil Lalwani | RSU | 25,014 | — | 1,974,605 |
| Nikhil Lalwani | RSU | 47,766 | — | 3,770,648 |
| Nikhil Lalwani | RSU | 53,686 | — | 4,237,973 |
| Nikhil Lalwani | RSU | 60,398 | — | 4,767,818 |
| Nikhil Lalwani | RSU | 60,932 | — | 4,809,972 |
| Nikhil Lalwani | RSU | 91,399 | — | 7,215,037 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Patrick WalshIndependent · Not standing for re-election | $97,477 | $248,323 | $0 | $0 | $0 | $345,800 |
| Thomas J. HaugheyIndependent · Audit and Finance · Nominating and Corporate Governance | 94,766 | 248,323 | 0 | 0 | 0 | 343,089 |
| Renee P. TannenbaumIndependent · Compensation · Nominating and Corporate Governance (Chair) | 84,250 | 248,323 | 0 | 0 | 0 | 332,573 |
| Jeanne A. ThomaIndependent · Audit and Finance (Chair) · Compensation | 83,007 | 248,323 | 0 | 0 | 0 | 331,330 |
| Matthew J. LeonardIndependent · Audit and Finance · Nominating and Corporate Governance | 79,250 | 248,323 | 0 | 0 | 0 | 327,573 |
| Antonio R. PeraIndependent · Compensation (Chair) | 79,250 | 248,323 | 0 | 0 | 0 | 327,573 |
| Muthusamy ShanmugamEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Nikhil LalwaniEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $59,250 |
|---|---|
| Annual equity retainer | $290,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 15,000 |
| Stock ownership guideline | Stock ownership guidelines which align the interests of our executive officers with those of our stockholders |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $518,000 |
| Equity awards (grant-date value) | $1,489,938 |
| All other compensation | $0 |
| Total cost of the board | $2,007,938 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names ANI Pharmaceuticals as a peer
Companies that benchmark against ANIP
16 companies name ANIP as a compensation peer
The list of companies that name ANIP as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ACAD Acadia Pharmaceuticals Inc.FOLD Amicus Therapeutics, Inc.AMPH Amphastar Pharmaceuticals, Inc.AUPH Aurinia Pharmaceuticals Inc.BCRX BioCryst Pharmaceuticals, Inc.CPRX Catalyst Pharmaceuticals, Inc.
Peer reciprocity
The companies ANI Pharmaceuticals Inc names as compensation peers that name it back in their own disclosed peer groups.
Amphastar Pharmaceuticals, Inc. (AMPH)74Aurinia Pharmaceuticals Inc. (AUPH)75Catalyst Pharmaceuticals, Inc. (CPRX)76
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | $728,466 | $0 | $11,132,458 | $1,052,633 | $12,951,082 |
| 2 | ANI Pharmaceuticals Inc | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 3 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 4 | Amphastar Pharmaceuticals, Inc. | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 5 | Acadia Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 6 | Catalyst Pharmaceuticals, Inc. | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 7 | Aurinia Pharmaceuticals Inc. | 2025 | Peter Greenleaf | 822,877 | 1,965,321 | 2,193,189 | 864,021 | 5,858,590 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| ANI Pharmaceuticals Inc | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Acadia Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Amphastar Pharmaceuticals, Inc. | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| Aurinia Pharmaceuticals Inc. | not disclosed | not disclosed | not disclosed | WTW |
| BioCryst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Catalyst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Mercer LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 13,819,988 | 1,058,460 | 17,377 | 92.78% | Passed |
| 2025 | 2025-05-22 | 14,565,587 | 1,689,477 | 15,174 | 89.52% | Passed |
| 2024 | 2024-05-21 | 16,139,473 | 762,718 | 11,702 | 95.42% | Passed |
| 2023 | 2023-05-23 | 13,207,478 | 780,337 | 19,909 | 94.29% | Passed |
| 2022 | 2022-04-27 | 11,675,231 | 1,416,720 | 85,874 | 88.6% | Passed |
| 2021 | 2021-06-02 | 9,417,485 | 328,111 | 49,478 | 96.15% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-21 | 92.78%a |
| 2025 | 2025-05-22 | 89.52%b |
| 2024 | 2024-05-21 | 95.42%c |
a. Approved under the standard stated in the filing — “For Proposals 2, 3, 4 and 5, abstentions will have the same effect as a vote "AGAINST" such proposals.”.
b. Approved under the standard stated in the filing — “For Proposals 2, 3, 4 and 5, abstentions will have the same effect as a vote "AGAINST" such proposals.”.
c. Approved under the standard stated in the filing — “For all other proposals, abstentions will have the same effect as vote "AGAINST" such proposal and broker non-votes have no effect.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 114 : 1 |
|---|---|
| CEO total compensation | $10,278,620 |
| Median employee compensation | $89,954 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Meredith Cook | Sr. VP, General Counsel & SEC. | 2026-04-13 | D | 500 | $78 | $38,975 | Common | Form 4 ↗ |
| Nikhil Lalwani | Director | 2026-05-11 | D | 55,000 | 78 | 4,266,350 | Common | Form 4 ↗ |
| Patrick Walsh | Director | 2026-05-11 | D | 3,973 | 81 | 320,820 | Common | Form 4 ↗ |
| Ori Gutwerg | SVP, Generics | 2026-05-12 | D | 2,772 | 80 | 220,374 | Common | Form 4 ↗ |
| Thomas Andrew Rowland | SVP, Head - Established Brands | 2026-05-12 | D | 459 | 79 | 36,357 | Common | Form 4 ↗ |
| Patrick Walsh | Director | 2026-05-13 | D | 10,000 | 81 | 806,300 | Common | Form 4 ↗ |
| Meredith Cook | Sr. VP, General Counsel & SEC. | 2026-05-13 | D | 500 | 78 | 39,080 | Common | Form 4 ↗ |
| Renee P. Tannenbaum | Director | 2026-05-21 | A | 4,357 | 0 | 0 | Common | Form 4 ↗ |
| Jeanne A. Thoma | Director | 2026-05-21 | A | 4,357 | 0 | 0 | Common | Form 4 ↗ |
| Matthew J. Leonard | Director | 2026-05-21 | A | 4,357 | 0 | 0 | Common | Form 4 ↗ |
| Antonio R. Pera | Director | 2026-05-21 | A | 4,357 | 0 | 0 | Common | Form 4 ↗ |
| Thomas J. Haughey | Director | 2026-05-21 | A | 4,357 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Carey | SVP & CFO | 2026-06-05 | D | 3,312 | 50 | 163,977 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Carey | SVP & CFO | 2026-06-05 | D | 3,312 | 80 | 264,960 | Common | Form 4 ↗ |
| Stephen Carey | SVP & CFO | 2026-06-05 | A | 3,312 | 50 | 163,977 | Common | Form 4 ↗ |
| Thomas J. Haughey | Director | 2026-06-08 | D | 2,000 | 81 | 161,760 | Common | Form 4 ↗ |
| Meredith Cook | Sr. VP, General Counsel & SEC. | 2026-06-12 | D | 500 | 82 | 41,015 | Common | Form 4 ↗ |
| Stephen Carey | SVP & CFO | 2026-06-29 | D | 2,850 | 84 | 239,742 | Common | Form 4 ↗ |
| Stephen Carey | SVP & CFO | 2026-07-02 | D | 3,313 | 50 | 164,027 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Carey | SVP & CFO | 2026-07-02 | D | 3,313 | 86 | 284,918 | Common | Form 4 ↗ |
| Stephen Carey | SVP & CFO | 2026-07-02 | A | 3,313 | 50 | 164,027 | Common | Form 4 ↗ |
| Meredith Cook | Sr. VP, General Counsel & SEC. | 2026-07-13 | D | 500 | 82 | 40,920 | Common | Form 4 ↗ |
| Meredith Cook | Sr. VP, General Counsel & SEC. | 2026-07-18 | D | 2,466 | 79 | 195,307 | Common | Form 4 ↗ |
| Stephen Carey | SVP & CFO | 2026-07-29 | D | 2,850 | 81 | 231,876 | Common | Form 4 ↗ |
| Ori Gutwerg | SVP, Generics | 2026-08-10 | D | 3,162 | 77 | 243,474 | Common | Form 4 ↗ |
| Meredith Cook | Sr. VP, General Counsel & SEC. | 2026-08-13 | D | 500 | 75 | 37,740 | Common | Form 4 ↗ |
| Henry O. Gosebruch | Director | 2026-08-19 | A | 6,662 | 0 | 0 | Common | Form 4 ↗ |
| Nikhil Lalwani | Director | 2026-08-25 | D | 5,400 | 74 | 401,220 | Common | Form 4 ↗ |
| Stephen Carey | SVP & CFO | 2026-08-31 | D | 2,850 | 73 | 207,480 | Common | Form 4 ↗ |
| Jeanne A. Thoma | Director | 2026-09-11 | D | 1,000 | 72 | 71,530 | Common | Form 4 ↗ |
| Meredith Cook | Sr. VP, General Counsel & SEC. | 2026-09-14 | D | 500 | 71 | 35,395 | Common | Form 4 ↗ |
| Nikhil Lalwani | Director | 2026-09-15 | D | 5,400 | 71 | 383,400 | Common | Form 4 ↗ |
| Stephen Carey | SVP & CFO | 2026-09-29 | D | 2,850 | 73 | 208,050 | Common | Form 4 ↗ |
| Meredith Cook | Sr. VP, General Counsel & SEC. | 2026-10-13 | D | 500 | 74 | 36,795 | Common | Form 4 ↗ |
| Nikhil Lalwani | Director | 2026-10-15 | D | 5,400 | 72 | 388,206 | Common | Form 4 ↗ |
| Stephen Carey | SVP & CFO | 2026-10-29 | D | 2,850 | 73 | 207,680 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (76 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Nikhil Lalwani. DEF 14A, filed 2026-04-09. Section “Summary Compensation Table” · page 35. As printed: 10,278,620. View filing ↗
- Section 01, Christopher Mutz. DEF 14A, filed 2026-04-09. Section “Summary Compensation Table”. As printed: 3,396,694. View filing ↗
- Section 01, Stephen Carey. DEF 14A, filed 2026-04-09. Section “Summary Compensation Table”. As printed: 3,251,862. View filing ↗
- Section 01, Meredith Cook. DEF 14A, filed 2026-04-09. Section “Summary Compensation Table”. As printed: 2,318,421. View filing ↗
- Section 01, Ori Gutwerg. DEF 14A, filed 2026-04-09. Section “Summary Compensation Table”. As printed: 2,309,559. View filing ↗
- Section 03, Christopher Mutz RSU. DEF 14A, filed 2026-04-09. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ori Gutwerg RSU. DEF 14A, filed 2026-04-09. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Nikhil Lalwani RSU. DEF 14A, filed 2026-04-09. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ori Gutwerg PSU. DEF 14A, filed 2026-04-09. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Meredith Cook RSU. DEF 14A, filed 2026-04-09. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Stephen Carey RSU. DEF 14A, filed 2026-04-09. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Meredith Cook PSU. DEF 14A, filed 2026-04-09. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Stephen Carey PSU. DEF 14A, filed 2026-04-09. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Mutz PSU. DEF 14A, filed 2026-04-09. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Nikhil Lalwani PSU. DEF 14A, filed 2026-04-09. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-09. Section “CEO Pay Ratio”. As printed: 114 : 1. View filing ↗
- Section 08, Patrick Walsh. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 345,800. View filing ↗
- Section 08, Thomas J. Haughey. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 343,089. View filing ↗
- Section 08, Renee P. Tannenbaum. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 332,573. View filing ↗
- Section 08, Jeanne A. Thoma. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 331,330. View filing ↗
- Section 08, Matthew J. Leonard. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 327,573. View filing ↗
- Section 08, Antonio R. Pera. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 327,573. View filing ↗
- Section 08, Muthusamy Shanmugam. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Nikhil Lalwani. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Meredith Cook 2026-04-13. Form 4, filed 2026-04-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nikhil Lalwani 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Walsh 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ori Gutwerg 2026-05-12. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Andrew Rowland 2026-05-12. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Walsh 2026-05-13. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meredith Cook 2026-05-13. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Renee P. Tannenbaum 2026-05-21. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeanne A. Thoma 2026-05-21. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew J. Leonard 2026-05-21. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Antonio R. Pera 2026-05-21. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Haughey 2026-05-21. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Carey 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Carey 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Carey 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Haughey 2026-06-08. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meredith Cook 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Carey 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Carey 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Carey 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Carey 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meredith Cook 2026-07-13. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meredith Cook 2026-07-18. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Carey 2026-07-29. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ori Gutwerg 2026-08-10. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meredith Cook 2026-08-13. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Henry O. Gosebruch 2026-08-19. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nikhil Lalwani 2026-08-25. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Carey 2026-08-31. Form 4, filed 2026-09-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeanne A. Thoma 2026-09-11. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meredith Cook 2026-09-14. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nikhil Lalwani 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Carey 2026-09-29. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meredith Cook 2026-10-13. Form 4, filed 2026-10-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nikhil Lalwani 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Carey 2026-10-29. Form 4, filed 2026-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-21. Item 5.07 · say-on-pay result. As reported: 92.78% (votes for as printed: 13,819,988). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-23. Item 5.07 · say-on-pay result. As reported: 89.52% (votes for as printed: 14,565,587). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-23. Item 5.07 · say-on-pay result. As reported: 95.42% (votes for as printed: 16,139,473). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 518,000 + equity 1,489,938 + all other 0 = 2,007,938, summed across the director compensation table rows.
- BioCryst Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. View filing ↗
- ANI Pharmaceuticals Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in ANI Pharmaceuticals Inc's own proxy. As printed: 10,278,620. View filing ↗
- Amicus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. View filing ↗
- Amphastar Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. View filing ↗
- Acadia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Catalyst Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. View filing ↗
- Aurinia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Aurinia Pharmaceuticals Inc.'s own proxy. As printed: 5,858,590. View filing ↗
- Section 10a, Amphastar Pharmaceuticals, Inc. reciprocity. DEF 14A. Amphastar Pharmaceuticals, Inc. names ANI Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Aurinia Pharmaceuticals Inc. reciprocity. DEF 14A. Aurinia Pharmaceuticals Inc. names ANI Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Catalyst Pharmaceuticals, Inc. reciprocity. DEF 14A. Catalyst Pharmaceuticals, Inc. names ANI Pharmaceuticals Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗